Skip to main content Skip to section navigation Skip to footer
Immunovant, Inc.
  • Home
  • About Us
    • Our Leadership
  • Our Science
    • Introduction to FcRn
    • Pipeline & Therapeutic Areas
  • Patients & Caregivers
    • Our Commitment
    • Therapeutic Areas & Clinical Trials
  • For Investors
    • Overview
    • News & Events
    • Company Info
    • Financials
    • Stock Data
    • SEC Filings
    • Governance
  • Join Us
    • Values & Culture
    • Explore Careers
  • Contact Us

Press Releases

View Main Content
For Investors

For Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Leadership Team
    • Contacts
    • FAQ
  • Financials
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Policy
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
May 22, 2023 7:00 am EDT

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Feb 03, 2023 7:00 am EST

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

Nov 07, 2022 8:00 am EST

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Nov 04, 2022 7:00 am EDT

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

Oct 04, 2022 8:45 am EDT

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Sep 28, 2022 10:45 am EDT

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Sep 21, 2022 8:00 am EDT

Immunovant to Present at Roivant Investor Day on September 28th

Sep 09, 2022 8:00 am EDT

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Sep 07, 2022 7:11 am EDT

Immunovant Announces Two New Development Programs for Batoclimab

Aug 24, 2022 8:00 am EDT

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Immunovant, Inc. All rights reserved.
Privacy Policy Terms of Use Disclaimer Sitemap Manage Cookie Preferences